Exclusive: The 'CRISPR babies' conversation is shifting

Not even six years after the gene-editing babies scandal, there are signs that pressure to relax such regulations is slowly building

October 8, 2024 Check out STAT+

Sponsored By

Jeremy Grinan for STAT STAT+ | A pariah in science, the 'CRISPR babies' researcher gains support from a U.S. cryptocurrency entrepreneur American's funding offer for China's He Jiankui reveals momentum to relax restrictions on controversial embryo research By Megan Molteni White House should declare national emergency over IV fluid shortages caused by Helene, says hospital group With a Baxter plant shuttered by Hurricane Helene, the AHA asked the White House to declare an IV fluid shortage and invoke national emergency powers. By Brittany Trang STAT+ | U.S. Supreme Court asks solicitor general for views on controversial Oklahoma law for regulating PBMs Last year, a U.S. appeals court struck down key parts of the Oklahoma law, ruling it was preempted by federal law. By Ed Silverman Courtesy City Therapeutics STAT+ | Biotech veteran John Maraganore raises $135 million for his 'next-generation RNAi' startup The former CEO of Alnylam Therapeutics is launching City Therapeutics, based in Cambridge, Mass. It hopes to begin clinical trials next year. By Allison DeAngelis STAT+ | Compounding group sues FDA for removing Lilly's obesity drug from its shortages list The lawsuit follows an FDA announcement that Eli Lilly determined its manufacturing capacity can meet "present and projected" national demand. By Ed Silverman Q&A: Why the NIH is spending $30 million to counter ableism in health care A new NIH program will allocate the funding to 10 groups over five years to examine the impact of ableism on health outcomes. By Timmy Broderick CHARLY TRIBALLEAU/AFP via Getty Images STAT+ | Harris seeks to tie expanded Medicare drug price negotiation to home care, vision, hearing coverage expansion Savings from more aggressive drug price negotiations would be used to fund a home care benefit in Medicare. By Rachel Cohrs Zhang and John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser